Abstract
Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011–2016, namely January 1, 2011, through August 31, 2016).
Highlights
Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies
Protein therapeutics cannot be completely synthesized by chemical processes and have to be manufactured in living cells or organisms; the choices of the cell line, species origin, and culture conditions all affect the final product characteristics[5,6,7]
Given the complexity of therapeutic proteins with respect to their large molecular size, post-translational modifications, and the variety of biological materials involved in their manufacturing process, the ability to enhance particular functional attributes while maintaining product safety and efficacy achieved through protein-engineering strategies is highly desirable
Summary
Biosimilar therapeutics-what do we need to consider? NDT Plus. 2009; 2(Suppl_1): i27–i36. Biosimilar therapeutics-what do we need to consider? 5. Bandaranayake AD, Almo SC: Recent advances in mammalian protein production. 6. Butler M, Meneses-Acosta A: Recent advances in technology supporting biopharmaceutical production from mammalian cells. 7. Zhu J: Mammalian cell protein expression for biopharmaceutical production. Cipriano D, Burnham M, Hughes JV: Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps. 9. Chirino AJ, Mire-Sluis A: Characterizing biological products and assessing comparability following manufacturing changes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
